Analytical Data
-
Gene name
TFPI
-
简介
TFPI (Tissue Factor Pathway Inhibitor) directly inhibits factor X (Xa) and inhibits the activity of VIIa/tissue factor through an Xa-dependent mechanism. It potentially forms a quaternary complex involving Xa, TFPI, VIIa, and tissue factor. TFPI exhibits antithrombotic properties and can associate with lipoproteins, demonstrating its multifaceted role in regulating the coagulation pathway. TFPI Protein, Human (HEK293, His-Avi) is the recombinant human-derived TFPI protein, expressed by HEK293 , with C-His, C-Avi labeled tag.
- Application
-
Alternative Names
LACI; TFPI1; EPI; TFI; convertin; TFPI
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10646
-
Expression Region
D29-K282
-
Protein Length
Partial
-
Molecular Weight
40-50 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Glypican-2 (GPC2) is a heparan sulfate proteoglycan that plays significant roles in cell signaling and development. It is predominantly expressed in the embryonic nervous system and has been found to be overexpressed in various tumors, including neuroblastoma, making it a potential target for cancer immunotherapy. Researchers are keenly interested in the recombinant production of GPC2 for several reasons. First, the availability of purified GPC2 allows for detailed studies of its structure and function, which are crucial for understanding its role in cancer progression and cell signaling pathways. Second, owing to its tumor-specific expression, GPC2 represents a promising candidate for the development of targeted therapies and diagnostic tools, particularly in neuroblastoma. Generating recombinant GPC2 protein facilitates the exploration of its immunogenic properties, which is essential for designing effective vaccines or antibody-based treatments. Additionally, such studies can elucidate the mechanisms by which GPC2 contributes to tumorigenesis, potentially aiding in the identification of novel therapeutic targets. Overall, the research surrounding recombinant GPC2 protein emphasizes its significance in cancer biology and its potential as a biomarker and therapeutic target in oncology.
